Home > Boards > US Listed > Medical - Equipment >

Neovasc, Inc. (NVCN)

Add NVCN Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 2/26/2021 2:12:47 PM - Followers: 195 - Board type: Free - Posts Today: 0

Trading for
$0.061 as of Thurs. March 29th, 2018, well under two recent Price Targets of $2.00 and $0.50.
Increased chatter amongst investors of a Partnership or Buyout, see below. 

Latest Analyst Ratings:

March 29th, 2018 3:07 AM EDT
Neovasc Inc. PT updated to $2.00 at Leerink Partners, states that 'Tiara Clinical Trials Continue to Progress' Maintains 'Outperform' Rating.

March 29th, 2018 
Canaccord Genuity Updates Neovasc Inc (US) (NVCN) Price Target to $0.50 and has a "Buy" rating.

Latest Earnings Report - March 28th, 2018
EPS of $-0.28 misses by $-0.02 
Revenue of $5.39M (- 43.3% Y/Y) beats by $1.29M

Trader's takeaway from the latest Earnings Report: (Updated on April 1st, 2018)
1. No R/S mentioned, 2. Tiara Prescreen implementation in Europe soon (as early as this week), 3. Updates on Tiara / Reducer enrollments shown to have been very successful and increasing in size, 4. Cash to last through Q3 2018, 5. Revenues were down/but so were expenses.

Also on the conference call, they reported that the $112 M lawsuit has been fully paid and settled. Neovasc said that “there are no other monetary damages arising from the award,” and announced that it will remain the joint inventor of its ‘964 patent related to its Tiara transcatheter mitral valve replacement device. Neovasc will share the patent along with 2 employees of CardiAQ Valve, with both parties “having freedom to use the patent without an obligation to pay royalties to the other", according to a press release. Source: NeoVasc shares surge 45% on affirmed Tiara patent case decision against Edwards.  https://www.massdevice.com/neovasc-shares-surge-45-affirmed-tiara-patent-case-decision-edwards/

Possible Partnership in the works?
This was taken from the latest Earnings Conference call on March 28th, 2018 (link to entire transcript provided above, courtesy of SeekingAlpha.com)
Newly acquired CEO/President Fred Colen hints at being open to a partnership.  Have a look at what he says:
Possible partnership?

Possible Buy Out in the works? 
Check out newly acquired CEO Fred Colen's bio below (spoiler alert: he worked with $BSX for 8 years as CTO) and see how this all ties together. 

Don't Be Surprised if Boston Scientific (BSX) Buys Neovasc (NVCN)- JMP  

MARCH 30, 2018 Article:

Neovasc has a unique opportunity to take a share of that US$16.2 Billion with this patent along with many other patents that they own.
Patent # 
SOURCE:  http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,579,964.PN.&OS=PN/8,579,964&RS=PN/8,579,964

Neovasc's Tiara and other TMVR devices
US$75 MILLION AGREEMENT 12/02/16}}}}

Neovasc and Boston Scientific Reach US$75 Million Agreement 
12/2/2016 7:00:00 AM - PR Newswire 

Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities 
12/2/2016 7:00:00 AM - PR Newswire 

NVCN + BSX = 15% stake = +350% for stock


Fred Colen - President and CEO

Neovasc Inc. (Nasdaq: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its board of directors (the "Board") has appointed Fred A. Colen as president and chief executive officer effective immediately. This leadership transition is a key element of the Company's strategy to support plans for the commercialization of its new-to-market Reducer™ ("Reducer") product in Europe and the advancement of its Tiara™ ("Tiara") mitral valve clinical program. Alexei Marko, Neovasc's outgoing CEO, will maintain his role as a Director on the Neovasc Board of Directors and continue to serve as an advisor to the Company.  

"After ten years building Neovasc, I am convinced that now is the time for new leadership to take the Company to the next level. I am especially pleased that an industry leader of Fred Colen's caliber has accepted this opportunity," said Alexei Marko, outgoing CEO of Neovasc. "I look forward to my continued involvement as a board member." 

Fred Colen has contributed to many significant turnarounds in his career, including the post-acquisition Guidant Company, which became the CRM division of Boston Scientific, a firm with which he held progressively senior executive roles over 11 years, including Chief Technology Officer from 2001-2008 and Member of the Executive Committee from 2001-2010. During his tenure at Boston Scientific, Mr. Colen is credited with numerous successes. As President of the company's Cardiac Rhythm Management (CRM) Group his team regained trust and confidence in the division's implantable pacemakers, leads, defibrillators and re-synchronization devices, increasing annual product revenue growth by over 10% in a flat US market and growing global divisional operating income from below 10% to 25% of sales, exceeding the planned annual free cash flow goals. As Chief Technology Officer, he led the development and global commercial launch for the Company's first- and second-generation implantable drug-eluting coronary stents (the Taxus Express and Taxus Liberte), leading to global market leadership with incremental revenues of US$2 billion annually. The Taxus Express market introduction is viewed as one of the most successful launches ever in the medical device industry. 

Also note:
$BSX Boston Scientific laid off 300 employees just recently on March 27th, 2018
, perhaps to make room for the takeover of $NVCN ?? Who knows?? They already own 15% of NVCN.
source: https://www.massdevice.com/boston-scientific-lays-off-nearly-300-from-valencia-neuromod-facilities/ 


                                                                      About Neovasc                                                                        

                                                     Neovasc Inc. is a specialty medical device company that develops, manufactures,
                                                     and markets products for the rapidly growing cardiovascular marketplace.

                                                                        Our products include the Tiara™ technology in development for the transcatheter
                                                                        treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of
                                                                        refractory angina.

                                                                         A Canadian Biotech company, headquartered in Vancouver, B.C. Canada, we are a
                                                                         publicly traded company, listed on NASDAQ: (NVCN) and the Toronto Stock
                                                                         Exchange TSX: (NVC) 




                                                    BUYOUT POTENTIAL                                        
              ------------------>>>>>>>>>>>>>Recent deals involving mitral valve companies<<<<<<<<<<<<<<--------------
"Great info and a MUST READ on the demand and for acquisitions for these type of companies here from last year this month now that remainder or any legal issues are getting ironed out through the final appeals days now , EVEN SHOWS THE $$ VALUES OF THE BOUGHT COMPANIES TOO:"


Concensus Recommendation courtesy of NASDAQ.com 
Updated: April 1st, 2018:   STRONG BUY.
Source: https://www.nasdaq.com/symbol/nvcn/analyst-research

STRONG BUY                                  
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NVCN News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 09:08 AM
NVCN News: Neovasc Comments on Clinical Cardiology Journal Publication 09:00 AM
NVCN News: Neovasc Comments on Clinical Cardiology Journal Publication 09:00 AM
NVCN News: Neovasc regains Nasdaq compliance 02/24/2021 04:29:16 PM
NVCN News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 02/24/2021 04:08:11 PM
News News Alert: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 03/02/2021 09:08:14 AM
#11896   I’m ready for 2 for 1 share sell zeusgodmd 02/26/21 02:12:47 PM
#11895   Looking good. tavito 02/16/21 10:03:11 PM
#11894   New investor put 76 million of his company’s zeusgodmd 02/16/21 08:19:41 AM
#11893   I am late for the party but just lakingsphan0427 02/11/21 01:39:13 PM
#11892   Moving up the stairs is a real positive conix 02/11/21 11:48:55 AM
#11891   * * $NVCN Video Chart 02-10-2021 * * ClayTrader 02/10/21 05:11:56 PM
#11890   Shorts will cover. Uptrend is beginning along with volume.$$$$ Jess070283 02/10/21 02:35:10 PM
#11889   I guess that depends on your entry point. Spumoni 02/10/21 11:13:51 AM
#11888   So did we all get screwed here, or what? cheesethiefofskyrim 02/10/21 09:52:11 AM
#11887   So did we all get screwed here, or what? cheesethiefofskyrim 02/10/21 09:51:49 AM
#11886   In on dip! Thanks!$$$ Jess070283 02/10/21 09:07:53 AM
#11885   Valve patent approval in Europe to the moon zeusgodmd 02/10/21 04:50:37 AM
#11884   These biotechs are coming alive...and staying alive. conix 02/09/21 07:33:20 PM
#11883   * * $NVCN Video Chart 02-09-2021 * * ClayTrader 02/09/21 05:59:36 PM
#11882   Nice! Never_Post 02/09/21 04:15:53 PM
#11881   7 hour prediction came true zeusgodmd 02/09/21 02:55:24 PM
#11880   Looking locked up. Shorts a 5 percent zeusgodmd 02/09/21 08:19:52 AM
#11879   USA open your eyes to the data. zeusgodmd 02/08/21 12:51:36 PM
#11878   Let the United States was money on admissions zeusgodmd 02/05/21 02:54:05 PM
#11877   Supplemental info provides good summary and what’s next zeusgodmd 02/05/21 07:29:19 AM
#11876   At least we have Germany and Europe zeusgodmd 02/02/21 11:40:34 AM
#11875   This stock has over 5 percent shorts. zeusgodmd 02/02/21 07:38:04 AM
#11874   With cpt codes I’m hope Fred has some zeusgodmd 01/31/21 08:25:11 PM
#11873   I guess nobody saw that we are getting zeusgodmd 01/29/21 12:10:05 PM
#11872   Selling for 20$/share let’s go zeusgodmd 01/22/21 03:24:05 PM
#11871   Fred needs to talk if there is going zeusgodmd 01/17/21 11:34:04 AM
#11870   Never mind the USA is clueless and these zeusgodmd 01/15/21 06:58:16 PM
#11869   Anybody know timeline on fda granting compassionate use zeusgodmd 01/13/21 07:43:35 AM
#11868   Man this was a great buy. Thai is TradingBabyishere 01/06/21 02:12:59 PM
#11867   Now close above 1.13 and tomorrow we have Jonas83 01/06/21 02:05:02 PM
#11866   Lets test 1.13 again Jonas83 01/05/21 12:47:58 PM
#11865   Warming up, looking good for breakout soon, maybe today. Jonas83 12/31/20 11:06:15 AM
#11864   On our way back to $2. Easy money TradingBabyishere 12/28/20 04:24:19 PM
#11863   Got in for 1300 shares at .91s Seems like TradingBabyishere 12/24/20 11:02:31 AM
#11862   * * $NVCN Video Chart 12-16-2020 * * ClayTrader 12/16/20 05:47:28 PM
#11861   Buy,buy grill the shorts here.. NVCN has 6 leonardo1 12/16/20 02:58:28 PM
#11860   Well it's about time!!! Crapola2theleft 12/16/20 09:37:02 AM
#11859   may run $4+++ $$$ MHOP kingsransome 12/16/20 09:02:31 AM
#11858   loading zone $$$ MHOP kingsransome 12/16/20 08:42:48 AM
#11857   Pre market was crazy sch100 12/16/20 08:22:06 AM
#11856   Looking at the chart she could easily go altruism 12/16/20 08:18:17 AM
#11855   NVCN bargain basement prices today only honest dave 12/08/20 03:06:18 PM
#11854   ok many thanks lister 11/04/20 11:05:02 AM
#11853   I mean in 2018 and 2019. . not Brumo 11/04/20 05:41:29 AM
#11852   Yes. Split in 2019 and another split in 2020 Brumo 11/04/20 05:36:41 AM
#11851   was there a split in 2020 lister 11/03/20 01:12:43 PM
#11850   Could you be more specific. Never_Post 11/01/20 06:00:02 PM
#11849   was there a split last time lister 11/01/20 02:17:27 PM
#11848   I hope Fred has called Boston scientific for zeusgodmd 10/30/20 10:34:45 AM
#11847   Thank You for your kind words... Never_Post 10/29/20 06:33:01 PM
Consent Preferences